MX349027B - Uso del fitocannabinoide cannabidiol (cbd) en combinacion con un farmaco estandar antiepileptico (saed) en el tratamiento de la epilepsia. - Google Patents

Uso del fitocannabinoide cannabidiol (cbd) en combinacion con un farmaco estandar antiepileptico (saed) en el tratamiento de la epilepsia.

Info

Publication number
MX349027B
MX349027B MX2013007609A MX2013007609A MX349027B MX 349027 B MX349027 B MX 349027B MX 2013007609 A MX2013007609 A MX 2013007609A MX 2013007609 A MX2013007609 A MX 2013007609A MX 349027 B MX349027 B MX 349027B
Authority
MX
Mexico
Prior art keywords
saed
cbd
epilepsy
treatment
combination
Prior art date
Application number
MX2013007609A
Other languages
English (en)
Other versions
MX2013007609A (es
Inventor
Williams Claire
Stephens Gary
Whalley Benjamin
Original Assignee
Gw Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43639013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX349027(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gw Pharma Ltd filed Critical Gw Pharma Ltd
Publication of MX2013007609A publication Critical patent/MX2013007609A/es
Publication of MX349027B publication Critical patent/MX349027B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con el uso de cannabidiol (CBD), a una dosis de más de 300 mg/día, en combinación con un fármaco antiepiléptico estándar (SAED) el cual actúa a través de los canales de sodio o calcio, para su uso en el tratamiento de la epilepsia. El SAED se preferencia es uno el cual • modifique las corrientes de calcio neuronal transitoria de bajo umbral o • reduzca el disparo neuronal de alta frecuencia y potenciales de acción dependientes de sodio y mejore los efectos de GABA. Los SAED preferidos son etosuximida y vaiproato.
MX2013007609A 2011-01-04 2012-01-03 Uso del fitocannabinoide cannabidiol (cbd) en combinacion con un farmaco estandar antiepileptico (saed) en el tratamiento de la epilepsia. MX349027B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1100043.7A GB2487712B (en) 2011-01-04 2011-01-04 Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
PCT/GB2012/050002 WO2012093255A1 (en) 2011-01-04 2012-01-03 Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy

Publications (2)

Publication Number Publication Date
MX2013007609A MX2013007609A (es) 2014-03-21
MX349027B true MX349027B (es) 2017-07-07

Family

ID=43639013

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007609A MX349027B (es) 2011-01-04 2012-01-03 Uso del fitocannabinoide cannabidiol (cbd) en combinacion con un farmaco estandar antiepileptico (saed) en el tratamiento de la epilepsia.

Country Status (20)

Country Link
US (2) US20140155456A9 (es)
EP (2) EP3791868A1 (es)
JP (1) JP6076259B2 (es)
KR (1) KR101853634B1 (es)
CN (2) CN103391775A (es)
AR (1) AR084559A1 (es)
AU (1) AU2012204800C1 (es)
BR (1) BR112013017154A8 (es)
CA (1) CA2822907C (es)
CO (1) CO6731122A2 (es)
DK (1) DK2661263T3 (es)
ES (1) ES2877502T3 (es)
GB (1) GB2487712B (es)
IL (1) IL227298A (es)
MX (1) MX349027B (es)
RU (1) RU2013136378A (es)
SG (1) SG191835A1 (es)
TW (1) TWI532479B (es)
WO (1) WO2012093255A1 (es)
ZA (1) ZA201305508B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005305675B2 (en) * 2004-11-16 2012-12-13 Gw Pharma Limited New use for cannabinoid
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Gw伐瑪有限公司 使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) * 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
WO2016044370A1 (en) 2014-09-16 2016-03-24 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
EP3247359A4 (en) * 2015-01-25 2018-08-08 India Globalization Capital, Inc. Composition and method for treating seizure disorders
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
WO2017027651A1 (en) 2015-08-12 2017-02-16 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
AU2016379345B2 (en) 2015-12-22 2020-09-17 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
SG10202005916QA (en) 2015-12-22 2020-07-29 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
CA3027862A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
CN109475586A (zh) 2016-06-29 2019-03-15 康纳塞斯创新公司 脱羧的大麻树脂、其用途和制备其的方法
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
AU2017315273B2 (en) * 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN108236608B (zh) * 2016-12-27 2020-05-08 汉义生物科技(北京)有限公司 大麻二酚与氨己烯酸的药物组合物及其用途
CN108245510B (zh) * 2016-12-29 2020-11-20 汉义生物科技(北京)有限公司 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途
CN108245517B (zh) * 2016-12-29 2020-05-08 汉义生物科技(北京)有限公司 大麻二酚与拉莫三嗪的药物组合物及其用途
CN108245499B (zh) * 2016-12-29 2020-11-20 汉义生物科技(北京)有限公司 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB2572737A (en) * 2018-01-24 2019-10-16 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
GB2580881A (en) 2018-11-30 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2581517A (en) 2019-02-22 2020-08-26 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2583526A (en) 2019-05-03 2020-11-04 Gw Res Ltd Use of cannabidiol in the treatment of tuberous sclerosis complex
CN110101804A (zh) * 2019-05-30 2019-08-09 厦门梓素生物科技有限公司 一种含大麻二酚提取物的癫痫药物组合及其制备方法
WO2021055499A1 (en) * 2019-09-17 2021-03-25 Zynerba Pharmaceuticals, Inc. Treatment of behavioral impairment in developmental and epileptic encephalopathy
GB2588460A (en) * 2019-10-25 2021-04-28 Gw Res Ltd Use of cannabidiol preparations in the treatment of temporal lobe epilepsy
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
CN113521050B (zh) * 2020-04-20 2023-05-09 铸鼎(北京)医学技术发展有限公司 含有大麻二酚的组合物及其在治疗全身炎症反应综合征中的用途
EP3912485A1 (en) 2020-05-18 2021-11-24 Del-Vis Sp. z o.o. Cigarette product and a method for manufacturing the product
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
GB2597296A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
GB2604132A (en) 2021-02-25 2022-08-31 Gw Res Ltd Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1140635B (de) 1959-10-24 1962-12-06 Ellenberger & Poensgen Mehrpoliger Motorschutzschalter
SE9802331L (sv) * 1998-06-29 1999-12-30 Ericsson Telefon Ab L M Metod och arrangemang avseende service vid ett intelligent nät
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
CZ306277B6 (cs) 2001-02-14 2016-11-09 Gw Pharma Limited Pumpičkou aktivovaná kapalná sprejová formulace
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
AU2005305675B2 (en) 2004-11-16 2012-12-13 Gw Pharma Limited New use for cannabinoid
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy

Also Published As

Publication number Publication date
IL227298A0 (en) 2013-09-30
ZA201305508B (en) 2014-04-30
ES2877502T8 (es) 2022-01-28
TWI532479B (zh) 2016-05-11
CA2822907A1 (en) 2012-07-12
GB2487712A8 (en) 2012-12-26
AU2012204800B2 (en) 2017-05-25
WO2012093255A1 (en) 2012-07-12
JP2014501271A (ja) 2014-01-20
EP3791868A1 (en) 2021-03-17
AU2012204800C1 (en) 2020-02-27
KR101853634B1 (ko) 2018-05-02
GB201100043D0 (en) 2011-02-16
CO6731122A2 (es) 2013-08-15
CN107510846A (zh) 2017-12-26
NZ613307A (en) 2015-11-27
ES2877502T3 (es) 2021-11-17
CN103391775A (zh) 2013-11-13
MX2013007609A (es) 2014-03-21
IL227298A (en) 2017-11-30
RU2013136378A (ru) 2015-02-10
GB2487712A (en) 2012-08-08
BR112013017154A8 (pt) 2018-04-03
BR112013017154A2 (pt) 2016-09-20
SG191835A1 (en) 2013-08-30
EP2661263B1 (en) 2021-04-14
NZ709911A (en) 2016-12-23
GB2487712B (en) 2015-10-28
EP2661263A1 (en) 2013-11-13
DK2661263T3 (da) 2021-07-05
TW201306826A (zh) 2013-02-16
AR084559A1 (es) 2013-05-22
US20130296398A1 (en) 2013-11-07
KR20130132972A (ko) 2013-12-05
US20140155456A9 (en) 2014-06-05
US20220395470A1 (en) 2022-12-15
JP6076259B2 (ja) 2017-02-08
CA2822907C (en) 2020-08-18

Similar Documents

Publication Publication Date Title
MX349027B (es) Uso del fitocannabinoide cannabidiol (cbd) en combinacion con un farmaco estandar antiepileptico (saed) en el tratamiento de la epilepsia.
PH12020500352A1 (en) Therapeutic uses of empagliflozin
PH12018502731A1 (en) Treatment of cancer with dihydropyrazino-pyrazines
BR112017025166A2 (pt) métodos de condicionar pacientes para terapia de células t
MY166014A (en) Combination therapy methods for treating proliferative diseases
IN2012DN02018A (es)
CO6670567A2 (es) Métodos de tratamiento contra el cáncer pancreático
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
MX365525B (es) Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
MX2020013740A (es) Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular.
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
MX2010002736A (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de tinnitus coclear.
PH12018500430A1 (en) Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX2016002307A (es) Tratamiento para el cancer.
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
MX2017013669A (es) Composiciones para el tramiento del cancer.
ZA202104321B (en) Aqueous paediatric retinol formulations
LV14461A (lv) Līdzeklis efektīvai augsta glutamāta līmeņa pazemināšanai asinīs

Legal Events

Date Code Title Description
FG Grant or registration